Bevacizumab-Induced Cutaneous Lupus Erythematosus in a Patient With Metastatic Colon Carcinoma: A Case Report.

Ashish, Sethi; Raj, Moses; Zhuang, Eric

Ashish, Sethi; Raj, Moses; Zhuang, Eric.

Afiliación

Ashish S; Infectious Disease, University of Missouri Kansas City School of Medicine, Kansas City, USA.
Raj M; Hematology and Oncology, Allegheny Health Network, Pittsburgh, USA.
Zhuang E; Hematology and Medical Oncology, Allegheny Health Network, Pittsburgh, USA.

Cureus ; 16(3): e56559, 2024 Mar.

Article en En | MEDLINE | ID: mdl-38646279

ABSTRACT

ABSTRACT

Bevacizumab, an anti-vascular epidermal growth factor inhibitor, is approved for the treatment of various cancers. Hypertension, gastrointestinal perforation, bleeding manifestations, impaired wound healing, and cerebrovascular accidents are common side effects associated with the monoclonal antibody. Uncommon cutaneous reactions like exfoliative dermatitis associated with bevacizumab have been documented in the medical literature. We present an unusual case of bevacizumab-induced cutaneous lupus in a patient with metastatic colon cancer that started resolving after discontinuing chemotherapy. Timely intervention was key in preventing the progression of this chemotherapy-induced cutaneous lupus.

Palabras clave

bevacizumab; cetuximab; cutaneous lupus erythematosus; drug-induced lupus; metastatic colon cancer

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cureus Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google